

# Martin E W Hemels

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3532225/publications.pdf>

Version: 2024-02-01

16  
papers

254  
citations

1478280

6  
h-index

1125617

13  
g-index

17  
all docs

17  
docs citations

17  
times ranked

415  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk Factors for Infections Involving Cardiac Implanted Electronic Devices. Journal of the American College of Cardiology, 2019, 74, 2845-2854.	1.2	94
2	Atrial fibrillation and cancer – An unexplored field in cardiovascular oncology. Blood Reviews, 2019, 35, 59-67.	2.8	64
3	On-demand mobile health infrastructures to allow comprehensive remote atrial fibrillation and risk factor management through teleconsultation. Clinical Cardiology, 2020, 43, 1232-1239.	0.7	36
4	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. Netherlands Heart Journal, 2017, 25, 551-558.	0.3	26
5	Optimal long-term antithrombotic management of atrial fibrillation: life cycle management. Netherlands Heart Journal, 2018, 26, 311-320.	0.3	9
6	Factors facilitating and hindering the implementation of the European Society of Cardiology Syncope Guidelines at the Emergency Department: A nationwide qualitative study. International Journal of Cardiology, 2021, 333, 167-173.	0.8	6
7	Self-Reported Mobile Health-Based Risk Factor and CHA2DS2-VASc-Score Assessment in Patients With Atrial Fibrillation: TeleCheck-AF Results. Frontiers in Cardiovascular Medicine, 2021, 8, 757587.	1.1	5
8	Long-term outcome of targeted therapy of underlying conditions in patients with early persistent atrial fibrillation and heart failure: data of the RACE 3 trial. Europace, 2022, 24, 910-920.	0.7	4
9	Mobile health: solution or a threat?. Netherlands Heart Journal, 2019, 27, 16-17.	0.3	2
10	Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study. Acta Cardiologica, 2021, 76, 431-439.	0.3	2
11	What the elite athlete does not want to know. Netherlands Heart Journal, 2018, 26, 111-112.	0.3	1
12	Adherence to anticoagulation: an ongoing challenge. Netherlands Heart Journal, 2019, 27, 594-595.	0.3	1
13	Atrial fibrillation management: Time for new goals. Revista Portuguesa De Cardiologia, 2020, 39, 663-665.	0.2	1
14	How to get a smoker addicted to quitting. Netherlands Heart Journal, 2017, 25, 14-15.	0.3	0
15	P2834 Diagnostic yield of holter recording after atrial fibrillation ablation - detection of asymptomatic recurrences during a one-year follow-up period. European Heart Journal, 2019, 40, .	1.0	0
16	Emergency department presentations because of atrial fibrillation: too many, too soon. Netherlands Heart Journal, 2021, 29, 253-254.	0.3	0